8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 6, 2013)

Filed May 6, 2013For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. filed an 8-K report on May 6, 2013, to announce its financial results for the first quarter ended March 31, 2013. This filing primarily serves to furnish the press release detailing these results, which is attached as Exhibit 99.1. Investors seeking detailed financial performance, operational updates, and forward-looking statements would need to refer to the content of the press release itself, as the 8-K itself is a procedural document in this instance. The report does not contain new operational or strategic information directly within the 8-K form but references the press release for the comprehensive update. Therefore, any analysis of Alnylam's performance or outlook based on this filing requires examination of the associated press release dated May 6, 2013. Investors should note that the information furnished in this report is not deemed "filed" for certain SEC purposes, meaning it does not carry the same liability implications as a formally filed document under Section 18 of the Exchange Act unless specifically incorporated by reference into another filing.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its Q1 2013 financial results on May 6, 2013.
  • 2The 8-K filing's primary purpose is to furnish the press release containing these results (Exhibit 99.1).
  • 3No new operational or financial data is presented directly within the 8-K body; all details are in the press release.
  • 4The information furnished is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability.
  • 5Investors must refer to the May 6, 2013 press release for substantive financial and operational details.
  • 6The report confirms the company's legal jurisdiction (Delaware) and principal executive office address.
  • 7Michael P. Mason, Vice President of Finance and Treasurer, signed the report on behalf of Alnylam.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide Alnylam Pharmaceuticals' financial results for the first quarter ended March 31, 2013, by furnishing the associated press release as an exhibit.

The detailed financial results and operational updates are contained within the press release dated May 6, 2013, which is furnished as Exhibit 99.1 to this 8-K report. You will need to access that press release for specific figures and commentary.

This specific 8-K filing itself does not contain new strategic announcements or guidance. It is purely to report the financial results via the press release. Any strategic information or forward-looking guidance would be present within the content of the furnished press release (Exhibit 99.1).

No, the information furnished in this Form 8-K (including the press release) is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section, unless expressly incorporated by reference into a separate filing.